Stock Movers Palantir Falls, Novo Nordisk's Metsera Bid, Uber Sinks on 3Q Profits
Nov 4, 2025
Nora Melinda, a markets correspondent from Bloomberg Television, delves into some intriguing stock movements. Palantir's shares are experiencing a pullback despite impressive earnings and a raised forecast, raising eyebrows over their premium valuation. Meanwhile, Novo Nordisk is in the spotlight with its updated bid for Metsera amid a potential bidding war with Pfizer. Uber, however, faces challenges as legal charges significantly impact its Q3 profits, leading to a dip in its stock prices. Insightful analysis makes for a captivating discussion!
AI Snips
Chapters
Transcript
Episode notes
Palantir Faces Valuation Pressure
- Palantir's stock has surged about 150% this year but now shows heavy selling and high volume indicating a pause.
- Analysts praise results but warn its trailing price-to-sales ratio near 85 raises valuation concerns and bubble fears.
Metsera Spurs Pharma Bidding War
- Novo Nordisk and Pfizer are competing to acquire Metsera because of its obesity-pill potential.
- Metsera shares jumped about 21% while Novo Nordisk ADRs pulled back roughly 2% amid the bidding war.
Uber Profit Hit By Legal Charges
- Uber reported soaring rideshare and delivery trips but posted weaker third-quarter profits due to legal charges.
- Shares fell about 6% after the company gave a muted adjusted earnings forecast and cited charges that hit profits.